Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia
The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2010
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/4408/ http://irep.iium.edu.my/4408/ http://irep.iium.edu.my/4408/ http://irep.iium.edu.my/4408/1/Paper_III_Norafiza_Zainuddin.pdf |
| id |
iium-4408 |
|---|---|
| recordtype |
eprints |
| spelling |
iium-44082011-12-14T12:43:28Z http://irep.iium.edu.my/4408/ Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia Kaderi, Mohd Arifin Mansouri, Mahmoud Zainuddin, Norafiza Cahill, Nicola Gunnarsson, Rebeqa Jansson, Mattias Kimby, Eva Aleskog, Anna Lundin, Jeanette Glimelius, Bengt Melbye, Mads Juliusson, Gunnar Jesper Jurlander, Jesper Rosenquist, Richard RC0254 Neoplasms. Tumors. Oncology (including Cancer) The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. Elsevier 2010-03-01 Article PeerReviewed application/pdf en http://irep.iium.edu.my/4408/1/Paper_III_Norafiza_Zainuddin.pdf Kaderi, Mohd Arifin and Mansouri, Mahmoud and Zainuddin, Norafiza and Cahill, Nicola and Gunnarsson, Rebeqa and Jansson, Mattias and Kimby, Eva and Aleskog, Anna and Lundin, Jeanette and Glimelius, Bengt and Melbye, Mads and Juliusson, Gunnar and Jesper Jurlander, Jesper and Rosenquist, Richard (2010) Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia. Leukemia Research, 34 (3). pp. 335-339. ISSN 0145-2126 http://www.sciencedirect.com/science/article/pii/S0145212609002835 10.1016/j.leukres.2009.06.006 |
| repository_type |
Digital Repository |
| institution_category |
Local University |
| institution |
International Islamic University Malaysia |
| building |
IIUM Repository |
| collection |
Online Access |
| language |
English |
| topic |
RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| spellingShingle |
RC0254 Neoplasms. Tumors. Oncology (including Cancer) Kaderi, Mohd Arifin Mansouri, Mahmoud Zainuddin, Norafiza Cahill, Nicola Gunnarsson, Rebeqa Jansson, Mattias Kimby, Eva Aleskog, Anna Lundin, Jeanette Glimelius, Bengt Melbye, Mads Juliusson, Gunnar Jesper Jurlander, Jesper Rosenquist, Richard Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia |
| description |
The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309
genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the
MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. |
| format |
Article |
| author |
Kaderi, Mohd Arifin Mansouri, Mahmoud Zainuddin, Norafiza Cahill, Nicola Gunnarsson, Rebeqa Jansson, Mattias Kimby, Eva Aleskog, Anna Lundin, Jeanette Glimelius, Bengt Melbye, Mads Juliusson, Gunnar Jesper Jurlander, Jesper Rosenquist, Richard |
| author_facet |
Kaderi, Mohd Arifin Mansouri, Mahmoud Zainuddin, Norafiza Cahill, Nicola Gunnarsson, Rebeqa Jansson, Mattias Kimby, Eva Aleskog, Anna Lundin, Jeanette Glimelius, Bengt Melbye, Mads Juliusson, Gunnar Jesper Jurlander, Jesper Rosenquist, Richard |
| author_sort |
Kaderi, Mohd Arifin |
| title |
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia |
| title_short |
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia |
| title_full |
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia |
| title_fullStr |
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia |
| title_full_unstemmed |
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukimia |
| title_sort |
lack of association between the mdm2 promoter polymorphism snp309 and clinical outcome in chronic lymphocytic leukimia |
| publisher |
Elsevier |
| publishDate |
2010 |
| url |
http://irep.iium.edu.my/4408/ http://irep.iium.edu.my/4408/ http://irep.iium.edu.my/4408/ http://irep.iium.edu.my/4408/1/Paper_III_Norafiza_Zainuddin.pdf |
| first_indexed |
2018-09-07T03:10:56Z |
| last_indexed |
2018-09-07T03:10:56Z |
| _version_ |
1610916672326074368 |